Extendicare Announces October 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - October 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of October 2026, which is payable on November 16, 2026 to shareholders of record at the close of business on October 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare
Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-15 8:00 AM EDT | Extendicare Inc.
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced that Sheila Leitzinger has joined the Company as Head of Clinical Operations. In this role, Ms. Leitzinger will lead clinical trial planning and execution for the initial healthy volunteer study of BETR-001, the Company's lead ca
2026-10-15 8:00 AM EDT | BetterLife Pharma Inc.
Herbal Dispatch Ships 3,000 Units of 2026 Happy Hour Holiday Cannabis Calendar to BCLDB Following Sold-Out 2025 Edition
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, announced the sale and shipment of 500 cases (3,000 units) of its 2026 Happy Hour Holiday Cannabis Calendar 12 Days of Coast Mtn (the "Calendar") to the British Columbia Liquor Distribution Branch (the "BCLDB"). The Calendar will be s
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-10-15 6:00 AM EDT | Herbal Dispatch Inc.
TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint
Toronto, Ontario--(Newsfile Corp. - October 15, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has executed a definitive exclusive distribution agreement dated September 14, 2026 (the "Distribution Agreement") with OGM For Import Medicine and Medical Supplies (the "Distributor
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-15 3:05 AM EDT | TempraMed Technologies Ltd.
Unbuzzd Wellness Announces Loan Amendment, Warrant Cancellation, and Acquisition of Licensed Intellectual Property
Vancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™, announces that it entered into a second loan amending agreement (the "Loan Amendment") and a warrant cancellation and release agreement (the "Warrant Cancellation Agreement") with Quantum BioPharma Ltd. ("Quantum") on October 13, 2026. LOAN AMENDMENT The Loan Amendment extends the maturity date of the Company's secured loan
2026-10-14 4:56 PM EDT | Unbuzzd Wellness Inc.
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
Vancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced the formation of a Scientific Advisory Board ("SAB") to guide the clinical development of BETR-001. Professor Peter Goadsby, MD, PhD, FRS, has been appointed Co-Chair. The SAB will advise the Company's manage
2026-10-14 8:00 AM EDT | BetterLife Pharma Inc.
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization High-potency proprietary olive-derived Verbascoside composition demonstra
Biotechnology, Pharmaceuticals, Health
2026-10-13 7:00 AM EDT | BioHarvest Sciences Inc.
BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today issued a statement regarding a Notice of Civil Claim ("Claim") filed against the Company by Steven Sangha, an independent director of BetterLife, in the Supreme Court of British Columbia on October 8, 2026. As disclosed in the Company's unaudited interim financial statements and management's discussion and analysis for Jul
2026-10-09 3:00 PM EDT | BetterLife Pharma Inc.
Theralase(R) to Present at ThinkEquity Conference
Toronto, Ontario--(Newsfile Corp. - October 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of proprietary Energy-Activated Small Molecules ("EASMs") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company has been invited to present at the 2026 Thin
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-09 7:00 AM EDT | Theralase Technologies Inc.
TMC Group Reports Progress on Capacity Expansion Ahead of EANM 2026
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Earlier this year, TMC Group, a Canadian manufacturer of enriched stable isotopes, announced plans to increase production capacity by 50 percent. Today, the company is commissioning new production lines that are already producing material, marking an early milestone in that work. The company will be exhibiting at the European Association of Nuclear Medicine (EANM) Annual Congress in Vienna next week, where the team will c
Technology, Biotechnology, Chemical, Pharmaceuticals
2026-10-08 12:00 PM EDT | TMC Group
Enoumena Therapeutics and AOP Health Announce Exclusive Canadian Commercialization Agreement for SIBBORAN(R) (landiolol)
Quebec and Vienna, Austria--(Newsfile Corp. - October 8, 2026) - Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian institutional access to PrSIBBORAN® (landiolol hydrochloride), an ultra-short-acting, selective beta-1 adrenergic receptor blocker. Authorized by Health Canada in 2023, SIBBORAN is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 10:47 AM EDT | Enoumena Therapeutics Inc.
Enoumena Therapeutics et AOP Health annoncent une entente exclusive de commercialisation au Canada de SIBBORAN(R) (landiolol)
Québec et Vienne, Autriche--(Newsfile Corp. - 8 octobre 2026) - Enoumena Therapeutics Inc. et AOP Health ont annoncé aujourd'hui la conclusion d'une entente exclusive de commercialisation visant à élargir l'accès des établissements de santé canadiens à PrSIBBORAN® (chlorhydrate de landiolol), un bêtabloquant sélectif des récepteurs bêta-1 adrénergiques à action ultra-courte. Autorisé par Sant
Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 10:47 AM EDT | Enoumena Therapeutics Inc.
Simple Eye Test and Glasses Could Help Double a Child's Lifetime Earnings in Both the USA and Canada
New IAPB finding shows a child's lifetime earnings could double in total of 23 countries worldwide if vision problems are identified and corrected early "A simple eye test and glasses could be one of the best investments a parent can make" IAPB CEO Finding published on World Sight Day, as governments urged to ensure every child has access to sight tests and glasses
Education, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 9:00 AM EDT | International Agency for the Prevention of Blindness
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme. The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted ne
Biotechnology, Pharmaceuticals, Health
2026-10-08 8:00 AM EDT | BioHarvest Sciences Inc.
TempraMed Granted Mexican Patent for Newest Product, VIVI Box
Highlights Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic engagement with appliance manufacturers across America's premium refrigeration sector Patent term extends through Octobe
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-08 3:05 AM EDT | TempraMed Technologies Ltd.
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical developmen
Biotechnology, Pharmaceuticals, Health
2026-10-07 2:37 PM EDT | Hemostemix Inc.
PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company advancing 3D-printed medicines, today announced the launch of the M3DICINES™ National Network Program (the "Network Program"). The program will build a national network of qualified sites that make personalized medicines on CraftMake™ pharmaceutical 3D printers, supported by PharmaTher's M3DICINES&#
Biotechnology, Pharmaceuticals
2026-10-07 8:00 AM EDT | PharmaTher Holdings Ltd.
Palindrome Pharma Launches in Canada to Unlock Access to High-Quality Biosimilar Medicines
Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - Palindrome Pharma, a new pharmaceutical company focused on biosimilar medicines, today announced its launch in Canada, with a mission to broaden access to high-quality biologic therapies and contribute to a more sustainable Canadian healthcare system. As demand for biologic medicines continues to grow, biosimilars have an important role to play in creating greater choices for Canadians. Palindrome Pharma will work with global and C
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-07 12:30 AM EDT | Palindrome Pharma Inc.
Unbuzzd Wellness Inc. Announces Refiling of Amended and Restated Interim Financial Statements and MD&A
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd, announces that it has filed amended and restated unaudited condensed interim consolidated financial statements for the three and nine months ended April 30, 2026 and 2025 (the "Amended Financial Statements"), together with amended and restated management's discussion and analysis (the "Amended MD&A"). The
2026-10-06 9:57 PM EDT | Unbuzzd Wellness Inc.